ClinicalTrials.gov
public full text
Public Domain
CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies#1044626
- RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease#1030193
- Tetraploidy in cancer: Diagnostic and therapeutic perspectives#391991
- TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer#867464
- Head and neck NUT carcinoma-radiotherapy dose, chemotherapy choice, and outcomes: lessons from a 7-year complete remission / Lara Schulz, Matthias Zähringer, Klaus-Henning Kahl, Nikolaos Balagiannis, Bertram Jehs, Johannes Doescher, Johannes Zenk, Georg Stüben, Maria Neu#1106442
Record · ID 226247
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive